Melanoma and Skin Cancer Awareness

From Skin to Slide – Clarity in Every Stain
Melanoma may account for very small part of skin cancers—but it causes the majority of skin cancer-related deaths.

Accurate diagnosis can be of importance in the management of melanocytic lesions, benign or malignant. Histologic morphology and Immunohistochemistry (IHC) of melanocytic lesions play a pivotal role.

At Diagnostic BioSystems we support pathology labs and clinicians with high-quality IHC reagents that help make an accurate diagnosis of malignant melanoma with confidence. Key melanoma markers such as:

• S100 – highly sensitive, ideal for screening.
• HMB-45 and Melan-A (MART-1) – sensitive and specific IHC markers for the confirmation of morphology diagnosis of melanoma.
• SOX10 – a powerful marker for both melanoma and neural crest-derived tumors.
• PRAME – A nuclear marker that helps diagnose malignant melanoma, in situ, invasive and metastatic. It is usually negative or only focal weak positive for benign melanocytic lesions.

As melanoma rates rise globally, especially among younger populations, the demand for diagnostic accuracy is greater than ever. We’re committed to advancing IHC innovation—from reagent quality to automation compatibility—so that clinicians can make faster and reasonable decisions.

Cutting-edge precision in melanoma care, powered by the MOHS Green Kit

MOHS Green Kit plays a vital role in Mohs micrographic surgery, providing essential reagents that ensure precision in skin cancer removal. When the time to final results is critical, such as Mohs micrographic surgery, this Mohs HRP-Green Kit can provide reliable IHC results in less than 20 minutes. Specifically for frozen sections. By helping clinicians accurately identify and remove cancerous tissue while preserving healthy skin, it contributes to faster recovery times and improved outcomes for patients.

This Melanoma Awareness Month, we stand with healthcare heroes in the fight for accurate detection and better patient outcomes.